ET Pharma’s Post

DAPSONE TABLET ASSAY EXPERIMENT Aim : To determine parentage purity of a given sample of tablet. Concept:Dapsone is used to treat leprosy (Hansen's disease) and to help control dermatitis herpetiformis, a skin problem. When it is used to treat leprosy, dapsone may be given with one or more other medicines. Dapsone acts against bacteria and protozoa in the same way as sulphonamides, that is by inhibiting the synthesis of dihydrofolic acid through competition with para-amino-benzoate for the active site of dihydropteroate synthetase. #performedbyme💊⚗️📑⏳

✅ There are 10,000 known rare diseases, out of which, ✅ Only 5% have US FDA-approved treatments, which means, ❌ 95% of rare diseases lack approved medication, affecting ❌ 400 Million people globally. 💡 With Nextnet you can quickly find leads buried in mountains of information and fast-track drug discovery and development for rare diseases.

On World TB Day, we highlight the importance of effective diagnosis and treatment to combat this disease. Rifampicin is a cornerstone medication in TB treatment regimens. However, ensuring optimal drug levels is crucial to maximize treatment success and minimize the risk of drug resistance. This World TB Day,we emphasizes the importance of Rifampicin Therapeutic Drug Monitoring (TDM). TDM helps personalize treatment plans by measuring drug concentration in the bloodstream, ensuring effective levels to combat TB bacteria. We are committed to offering advanced diagnostic tools like Rifampicin TDM on Agilent Technologies to ensure optimal TB treatment outcomes. #WorldTBDay #TB #Rifampicin #TDM #TBFreeWorld #worldtbday

How can we change the projections presented in this report? Are there any ways to get new/innovative therapies to combat resistance?

Celltrion's infliximab biosimilar, CT-P13, was found to be just as effective and safe as the original brand name drug. This means a potentially more affordable option for treating patients with Crohn disease! Click the link to read more about the results found in a retrospective, real-world study in Japan. https://lnkd.in/eXUZDwp5

Did you know that today is #RareDiseaseDay? Check out Certara Talks with our experts, Oxana Iliach, Rajesh Krishna, David Wesche, and Paul Martin, who discuss the combined efforts and expertise needed for a successful rare disease drug submission. They also share insights into the regulatory challenges that rare disease development programs need to think about. ▶️ Watch now: https://ow.ly/CkGc50QH9HZ Curious to delve further into the world of rare disease drug development? Explore more at: https://lnkd.in/eTDeSvhH #RareDiseaseDay #DrugDevelopment #CertaraTalks

Following 2023’s successful EL-PFDD meeting, our new Voice of the Patient Report is a critical next step in the IPPF’s engagement with FDA and other decision-makers. As we’ve learned, there are significant obstacles facing #pemphigus and #pemphigoid patients’ access to potential future therapies. To overcome these obstacles, we must empower the voice of a strong coalition of patients, caregivers, researchers, and clinicians so that regulatory agencies and industry partners understand what truly matters to people living with these diseases.

Delighted to share that my first author article on lymphatic filariasis (LF) elimination using mathematical modelling has finally been published in Clinical Infectious Diseases. LF, transmitted by mosquitoes and causing severe disabilities, affects around 50 million people globally, with 55% of the burden in India. Mass drug administration (MDA) campaigns have successfully resulted in (close to) elimination of lymphatic filariasis in many settings. In this article, using the well-established LYMFASIM simulation model, we calculate the positive predictive value (ratio of true positives to total positive tests) of the threshold value of infection prevalence below which the treatment can be stopped so that the risk of resurgence is minimal in previously untreated LF-affected areas of India. More details can be found in the article: https://lnkd.in/g_jUaaQC. Many thanks to all the co-authors for their support in this process!

You or someone you love could be part of developing new therapies for congenital hyperinsulinism. ⁠ ⁠ The ACHIEVE clinical trial is seeking children and adults with congenital hyperinsulinism for participation. The study is evaluating a long-acting investigational drug that acts like glucagon in the body to maintain blood sugar levels. Dosing is only required once per week. During the study qualified participants will be provided with a continuous glucose monitoring system, glucometer, and patient diary. ⁠ ⁠ Visit http://ACHIEVE.study for more information. ⁠ ⁠ ⁠ ⁠ #hyperinsulinism #raredisease #congenitalhyperinsulinism #hypoglycemia ⁠ | Hyperinsulinism | Congenital | HI | Hypoglycemia | Rare Disease

You or someone you love could be part of developing new therapies for congenital hyperinsulinism. ⁠ ⁠ The ACHIEVE clinical trial is seeking children and adults with congenital hyperinsulinism for participation. The study is evaluating a long-acting investigational drug that acts like glucagon in the body to maintain blood sugar levels. Dosing is only required once per week. During the study qualified participants will be provided with a continuous glucose monitoring system, glucometer, and patient diary. ⁠ ⁠ Visit http://ACHIEVE.study for more information. ⁠ ⁠ ⁠ ⁠ #hyperinsulinism #raredisease #congenitalhyperinsulinism #hypoglycemia ⁠ | Hyperinsulinism | Congenital | HI | Hypoglycemia | Rare Disease